Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Salix Climbs to High on Report of Approach From Allergan

Salix Pharmaceuticals Ltd., maker of gastrointestinal treatments, rose to its highest value in almost 14 years after a report that Allergan Inc. approached it as an acquisition target.

Salix shares climbed 16 percent to close at $160.80 in New York, the highest price since November 2000, raising its market value to $10.2 billion, according to data compiled by Bloomberg.

Allergan Chief Executive Officer David Pyott said he is seeking acquisitions while attempting to fend off a takeover by Valeant Pharmaceuticals International Inc. The Wall Street Journal earlier today reported that Irvine, California-based Allergan had approached Salix and at least one other company.

Salix is merging with Italian drugmaker Cosmo Pharmaceuticals SpA. The $2.7 billion deal, expected to close by the end of 2014, will allow Raleigh, North Carolina-based Salix to move its tax address to Ireland.

Scott Bisang, a representative for Allergan at Joele Frank, declined to comment. Lekha Rao, a representative for Salix with Teneo Strategy, also declined to comment.

Shares of Jazz Pharmaceuticals Plc, based in Dublin, rose 2.9 percent to close at $156.87. Jazz makes narcolepsy, psychiatry and oncology drugs. It has been speculated by analysts as a takeover target and, with its $9.4 billion market capitalization, may be within Allergan’s reach.

Valeant’s takeover bid for Allergan, backed by activist hedge-fund manager Bill Ackman, has become increasingly acrimonious. Allergan has sued Valeant and Ackman’s fund Pershing Square Management LP for insider trading. Meanwhile, Ackman is seeking a special meeting or shareholders to add six new members to Allergan’s board and help push through a deal.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.